Regeneron Pharmaceuticals Inc - Company Profile
Powered by 
All the data and insights you need on Regeneron Pharmaceuticals Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Regeneron Pharmaceuticals Inc Strategy Report
- Understand Regeneron Pharmaceuticals Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Related keylists
View moreView up-to-date information on Regeneron Pharmaceuticals Inc’s latest deals, number of deals and deal values, alongside insights into its key mergers and acquisitions.
Number of Deals
Deal Value ($M)
Latest Deals
| Announced Date | Headline | Deal Type | Acquirers/Investors/Surviving Entity | Issuer/Partner/Target |
|---|---|---|---|---|
| 07 Sep 2022 | OncoResponse Enters into Agreement with Regeneron | Partnership | - |
OncoResponse Inc
Regeneron Pharmaceuticals Inc |
| 12 Jul 2022 | Ultima Genomics Enters into Development Agreement with Regeneron Pharma | Partnership | - |
Ultima Genomics Inc
Regeneron Pharmaceuticals Inc |
| 17 May 2022 | Vyriad Raises USD29.5 Million in Series B Financing | Venture Financing |
Harry Stine
Southeast Minnesota Capital Fund LLC
Regeneron Pharmaceuticals Inc
Mirae Asset Venture Investment Co. Ltd.
Mayo Clinic |
Vyriad Inc
|
| 06 Apr 2021 | Lorem ipsum dolor sit amet, consectetur adipiscing elit | Eiusmod Tempor | Exercitation cillum velit | Exercitation cillum velit Tempor |
| 06 Apr 2021 | Lorem ipsum dolor sit amet, consectetur adipiscing elit | Eiusmod Tempor | Exercitation cillum velit | Exercitation cillum velit Tempor |
| 06 Apr 2021 | Lorem ipsum dolor sit amet, consectetur adipiscing elit | Eiusmod Tempor | Exercitation cillum velit | Exercitation cillum velit Tempor |
Contact the team or request a demo to find out how our data can drive your business forward
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer